Torsten Falk

List of Publications by Year
in descending order

34 papers	783 citations	430754 18 h-index	526166 27 g-index
39 all docs	39 docs citations	39 times ranked	1078 citing authors

#	Article	IF	Citations
1	Vascular endothelial growth factor B (VEGF-B) is up-regulated and exogenous VEGF-B is neuroprotective in a culture model of Parkinson's disease. Molecular Neurodegeneration, 2009, 4, 49.	4.4	56
2	A Novel Angiotensin-(1-7) Glycosylated Mas Receptor Agonist for Treating Vascular Cognitive Impairment and Inflammation-Related Memory Dysfunction. Journal of Pharmacology and Experimental Therapeutics, 2019, 369, 9-25.	1.3	47
3	The Yin and Yang of VEGF and PEDF: Multifaceted Neurotrophic Factors and Their Potential in the Treatment of Parkinsonâ€™s Disease. International Journal of Molecular Sciences, 2010, 11, 2875-2900.	1.8	46
4	Neurochemical and electrophysiological characteristics of rat striatal neurons in primary culture. Journal of Comparative Neurology, 2006, 494, 275-289.	0.9	44
5	Comparative study of the neurotrophic effects elicited by VEGF-B and GDNF in preclinical in vivo models of Parkinsonâ€™s disease. Neuroscience, 2014, 258, 385-400.	1.1	44
6	Pigment epithelium derived factor (PEDF) is neuroprotective in two in vitro models of Parkinson's disease. Neuroscience Letters, 2009, 458, 49-52.	1.0	41
7	Vascular endothelial growth factor-B is neuroprotective in an in vivo rat model of Parkinson's disease. Neuroscience Letters, 2011, 496, 43-47.	1.0	40
8	Retinal pigment epithelial cell transplantation could provide trophic support in Parkinson's disease: Results from an in vitro model system. Experimental Neurology, 2006, 201, 234-243.	2.0	39
9	Cloning, functional expression and mRNA distribution of an inwardly rectifying potassium channel protein. FEBS Letters, 1995, 367, 127-131.	1.3	38
10	PEDF and VEGF-A Output from Human Retinal Pigment Epithelial Cells Grown on Novel Microcarriers. Journal of Biomedicine and Biotechnology, 2012, 2012, 1-8.	3.0	33
11	Can quantifying morphology and TMEM119 expression distinguish between microglia and infiltrating macrophages after ischemic stroke and reperfusion in male and female mice?. Journal of Neuroinflammation, 2021, 18, 58.	3.1	29
12	Case Reports Showing a Long-Term Effect of Subanesthetic Ketamine Infusion in Reducing <smlcap>L</smlcap>-DOPA-Induced Dyskinesias. Case Reports in Neurology, 2016, 8, 53-58.	0.3	28
13	Long-term effect of sub-anesthetic ketamine in reducing l -DOPA-induced dyskinesias in a preclinical model. Neuroscience Letters, 2016, 612, 121-125.	1.0	26
14	Insights into the Mechanisms Involved in Protective Effects of VEGF-B in Dopaminergic Neurons. Parkinson's Disease, 2017, 2017, 1-13.	0.6	26
15	Ten-Hour Exposure to Low-Dose Ketamine Enhances Corticostriatal Cross-Frequency Coupling and Hippocampal Broad-Band Gamma Oscillations. Frontiers in Neural Circuits, 2018, 12, 61.	1.4	25
16	Expression of Niemannâ€“Pick type C transcript in rodent cerebellum in vivo and in vitro. Brain Research, 1999, 839, 49-57.	1.1	24
17	CNS penetration of the opioid glycopeptide MMP-2200: A microdialysis study. Neuroscience Letters, 2012, 531, 99-103.	1.0	23
18	Preclinical evidence in support of repurposing sub-anesthetic ketamine as a treatment for L-DOPA-induced dyskinesia. Experimental Neurology, 2020, 333, 113413.	2.0	23

#	Article	IF	Citations
19	An endogenous inactivating inward-rectifying potassium current in oocytes of Xenopus laevis. Pflugers Archiv European Journal of Physiology, 1996, 432, 812-820.	1.3	19
20	Effects of the novel glycopeptide opioid agonist MMP-2200 in preclinical models of Parkinson's disease. Brain Research, 2011, 1413, 72-83.	1.1	15
21	Over-expression of the potassium channel Kir2.3 using the dopamine-1 receptor promoter selectively inhibits striatal neurons. Neuroscience, 2008, 155, 114-127.	1.1	14
22	Differential expression of three classes of voltage-gated Ca2+ channels during maturation of the rat cerebellum in vitro. Developmental Brain Research, 1999, 115, 161-170.	2.1	13
23	Viral vector-mediated expression of K+ channels regulates electrical excitability in skeletal muscle. Gene Therapy, 2001, 8, 1372-1379.	2.3	13
24	The combination of the opioid glycopeptide MMP-2200 and a NMDA receptor antagonist reduced l-DOPA-induced dyskinesia and MMP-2200 by itself reduced dopamine receptor 2-like agonist-induced dyskinesia. Neuropharmacology, 2018, 141, 260-271.	2.0	13
25	Highly-selective Âµ-opioid receptor antagonism does not block L-DOPA-induced dyskinesia in a rodent model. BMC Research Notes, 2020, 13, 149.	0.6	12
26	Differential effects of the NMDA receptor antagonist MK-801 on dopamine receptor D1- and D2-induced abnormal involuntary movements in a preclinical model. Neuroscience Letters, 2014, 564, 48-52.	1.0	11
27	Spectral signatures of L-DOPA-induced dyskinesia depend on L-DOPA dose and are suppressed by ketamine. Experimental Neurology, 2021, 340, 113670.	2.0	11
28	The Delta-Specific Opioid Glycopeptide BBI-11008: CNS Penetration and Behavioral Analysis in a Preclinical Model of Levodopa-Induced Dyskinesia. International Journal of Molecular Sciences, 2021, 22, 20.	1.8	11
29	Design and Synthesis of Brain Penetrant Glycopeptide Analogues of PACAP With Neuroprotective Potential for Traumatic Brain Injury and Parkinsonism. Frontiers in Drug Discovery, 2022, 1, .	1.1	8
30	Sleep Spindles and Fragmented Sleep as Prodromal Markers in a Preclinical Model of LRRK2-G2019S Parkinson's Disease. Frontiers in Neurology, 2020, 11, 324.	1.1	7
31	Evaluation of microglia in a rodent model of Parkinsonâ€™s disease primed with L-DOPA after sub-anesthetic ketamine treatment. Neuroscience Letters, 2021, 765, 136251.	1.0	1
32	Development of a ParkinsonË^s disease model in medaka fish. FASEB Journal, 2012, 26, 998.1.	0.2	1
33	Evaluation of a Parkinson's disease model in medaka fish. FASEB Journal, 2013, 27, 567.1.	0.2	1
34	A herpes simplex viral vector expressing green fluorescent protein can be used to visualize morphological changes in high-density neuronal culture. Electronic Journal of Biotechnology, 2001, 4, 20-21.	1.2	1